Time to diagnosis and treatment of obstructive sleep apnoea using mandibular jaw movement monitoring versus polysomnography: an open-label, multicentre, randomised, controlled trial
(2026) The Lancet Regional Health - Europe — p. 101637 (2026)
Files
PépinJLLancetRegHealthEur2026.pdf
Open Access - Adobe PDF
- 648.18 KB
Details
- Authors
Pépin, Jean-Louis 
Tamisier, Renaud
- Abstract
- Background Obstructive sleep apnoea (OSA) is often underdiagnosed, highlighting the need for scalable diagnostic alternatives. The SUNSAS study compared a new device for at-home diagnosis of OSA (artificial intelligence [AI]-supported analysis of mandibular jaw movements [MJM]) with polysomnography (PSG) for time to diagnosis and treatment, and patient-reported outcomes. Methods This prospective, multicentre, randomised, controlled, open-label study was conducted in France (October 2021–October 2024). Adults aged 18–80 years with suspected OSA were randomised (1:1) to undergo diagnostic testing using MJM monitoring (Sunrise) or PSG. Primary endpoints were assessed using hierarchical testing: 1. daytime sleepiness (Epworth Sleepiness Scale [ESS] score) at 3 months post-diagnosis and time to diagnosis; 2. time to treatment; and 3. daytime sleepiness at 3 months post-randomisation. Secondary endpoints included quality of life (Short Form-36, Quebec Sleep Questionnaire), work productivity (Work Productivity and Activity Impairment questionnaire), and positive airway pressure therapy adherence at 3 months after treatment initiation. Findings Of 849 participants randomised (58·7% male, median age 50 years, body mass index 28·0 kg/m 2, apnoea-hypopnoea index 15·2/h), 774 received a diagnosis: 133 no OSA, 239 mild OSA, 220 moderate OSA, and 182 severe OSA. Median time to diagnosis (15 vs. 106 days) and to treatment initiation (50 vs. 124 days) were significantly shorter with MJM analysis versus PSG (both p < 0·01). MJM-based diagnosis was noninferior to PSG in reducing ESS at 3 months after diagnosis (−2·26 vs. −2·29; 95% confidence interval [CI] for difference −0·85, 0·79; p = 0·01), and superior at 3 months post-randomisation (between-group difference: −1·51 (95% CI −2·17, −0·85); p < 0·01). Secondary endpoints also favoured the MJM group. Interpretation OSA diagnosis based on MJM monitoring with AI-supported analysis is noninferior to PSG in reducing daytime sleepiness at 3 months after diagnosis, while significantly accelerating time to diagnosis and treatment initiation, resulting in earlier improvement in daytime sleepiness.
- Affiliations
Citations
Pépin, J.-L., Tamisier, R., Manceau, M., Denoncin, K., Prigent, A., Patout, M., Pégliasco, H., Gagnadoux, F., Martinot, J.-B., Roustit, M., Alexandre, S., Baillieul, S., Barateau, L., Bianquis, C., Bellanger, Y., Benzaquen, H., Boyer, L., Carpentier, N., Charbonnier, E., et al. (2026). Time to diagnosis and treatment of obstructive sleep apnoea using mandibular jaw movement monitoring versus polysomnography: an open-label, multicentre, randomised, controlled trial. The Lancet Regional Health - Europe, 101637. https://doi.org/10.1016/j.lanepe.2026.101637 (Original work published 2026)